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ABSTRACT
Selective laser trabeculoplasty (SLT) has been
widely used in the clinical management of
glaucoma, both as primary and adjunctive
treatment. As new evidence continues to arise,
we review the current literature in terms of
indications and efficacy, surgical technique,
postoperative care, repeatability, and compli-
cations of this therapy. SLT has been shown to
be effective in various glaucomas, including
primary open-angle glaucoma (POAG), nor-
mal-tension glaucoma (NTG), steroid-induced
glaucoma, pseudoexfoliation glaucoma (PXFG),
and primary angle-closure glaucoma (PACG), as
well as other glaucoma subtypes. Relatively
high preoperative intraocular pressure (IOP)
may predict surgical success, while other
parameters that have been studied do not seem
to affect the outcome. Different techniques for
performing the procedure have recently been
explored, revealing that minor modifications
may lead to a more favorable or safer clinical
outcome. The utilization of postoperative
medications remains controversial based on the
current evidence. A short-term IOP increase
may complicate SLT and can also persist in
certain cases such as in exfoliation glaucoma.
The efficacy and safety of repeat SLT are shown
in multiple studies, and the timing of repeat
procedures may affect the success rate.
Keywords: Glaucoma; Intraocular pressure;
Laser; Selective laser trabeculoplasty
INTRODUCTION
Intraocular pressure (IOP) reduction is the
mainstay of therapy for glaucomatous optic
neuropathy. Selective laser trabeculoplasty
(SLT) has been widely employed for this pur-
pose over the past several years as both a pri-
mary and adjunctive treatment [1].
In recent years, there has been a surge in
literature regarding the utilization of SLT in
patients with glaucoma. The procedure may
address issues with topical medication compli-
ance and side effects [1], and it is considered a
cost-effective treatment [2]. Although the effect
of SLT wanes over time, repeating the procedure
may lead to clinical success comparable to that
achieved with the initial treatment [3–5].
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In a study by Bovell and colleagues compar-
ing SLT to argon laser trabeculoplasty (ALT), SLT
lowered IOP by over 6.5 mmHg at 3 years of
follow-up [6]. Efficacy results were similar to
those achieved with ALT, with waning efficacy
and a 50% failure rate after 2 years. The poten-
tial repeatability of SLT is thought to be one of
its advantages over ALT [5], which was shown to
have a success rate of only 14% after re-treat-
ment [7].
Globally, SLT also plays an important role as
adjunctive or primary therapy for open-angle
glaucoma. Realini demonstrated a prompt and
sustained reduction in IOP after SLT therapy in
patients from St. Lucia that were washed out
from all medical therapy. Mean IOP reductions
ranged from 7.3 to 8.3 mmHg (34.1–38.9%)
through 12 months of follow-up [8].
Although SLT is considered a relatively safe
procedure, risks of complications remain [9].
Furthermore, follow-up visits are required to
monitor for adverse events, and additional
treatment with medications or incisional pro-
cedures ultimately may be required [10, 11].
There is an increasing need for better
understanding of SLT and how it fits within the
picture of treating glaucoma. In this article, we
will review recent findings pertaining to SLT,
including its indications and efficacy, surgical
technique, postoperative care, and
complications.
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
INDICATIONS AND EFFICACY
Various glaucoma subtypes may be amenable to
treatment with SLT in order to reduce baseline
IOP and/or medication burden. A recently
published review investigating SLT outcomes in
the Hong Kong Chinese population reports that
expected efficacy may depend on the underly-
ing glaucoma subtype [12]. Most studies define
successful SLT treatment as a reduction in IOP
[20% from baseline levels. Recent data per-




The efficacy of SLT in patients with POAG or
OHT has been demonstrated in numerous
studies. It has great therapeutic potential when
used as a primary or adjunctive treatment
modality. Kadasi et al. have suggested that the
efficacy of SLT is at least comparable to that of
topical medications, and SLT may be preferred
when considering the potential adverse sys-
temic and local adverse effects as well as com-
pliance issues associated with long-term
medication use [1].
A recent study investigated the use of SLT in
early and advanced open-angle glaucoma
(OAG), where the glaucoma staging was based
on the vertical cup-to-disc ratio. SLT was shown
to be successful in reducing IOP by more than
20% in both early and advanced OAG. Fur-
thermore, functional and/or structural progres-
sion was not detected in treated patients for up
to 12 months post-operation. The success rates
were 63% and 59.1% for early and advanced
OAG, respectively. Results from this study allow
clinicians to consider SLT as an alternative to
higher-risk incisional therapies in advanced
stages of OAG [13].
Kerr et al. used the water-drinking test
(WDT) to demonstrate that SLT is effective in
reducing both peak IOP and IOP fluctuation in
patients with OAG or ocular hypertension.
Following SLT, there was a significant reduction
in both baseline and peak IOP, and the per-
centage rise from baseline after the WDT was
significantly lower as well. Since WDT provides
an accurate prediction of diurnal IOP spikes,
SLT would be expected to minimize IOP fluc-
tuations outside of the clinic when IOP mea-
surement is not attainable [14].
Primary Angle-Closure Glaucoma
Traditionally, clinicians have not considered
SLT in angle-closure glaucomas, as the proce-
dure requires visualization and treatment of the
trabecular meshwork. However, recent studies






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































in cases where portions of the anterior chamber
angle remain open and amenable to treatment.
Ali Aljasim et al. conducted a retrospective
case–control study to compare the efficacy of
SLT in eyes with primary angle closure or pri-
mary angle-closure glaucoma (PAC or PACG,
respectively; 59 eyes) and POAG (59 eyes), with
an average of 10 and 11 months of follow-up,
respectively. In patients with poorly controlled
preoperative IOP, SLT resulted in a mean IOP
reduction of 38% following treatment in the
PAC/PACG group. In patients who had con-
trolled IOP of PAC/PACG under medication but
were intolerant of the medications, SLT
achieved a reduction of 1.6 medications. The
success rate of SLT in reducing IOP by at least
20% was 84.7% in the PAC/PACG group, and
the clinical outcomes were comparable to those
in the POAG group [15].
Narayanaswamy and colleagues performed a
randomized clinical trial that evaluated the
efficacy of SLT in comparison to topical pros-
taglandin analog (PGA) medical therapy in
patients with PAC/PACG. After 6 months of
follow-up, the mean IOP in both groups was
significantly reduced from baseline, and the
reduction was comparable between the two
groups. The overall success rate of SLT was 60%,
which was significantly less than the 84% suc-
cess rate achieved in the PGA group (P = 0.008).
More medications were required to control IOP
in the SLT group than in the PGA group (22%
increase, P\0.05), and these patients experi-
enced a decrease (4.8%, P\0.001) in endothe-
lial cell count as well. In this study, SLT
demonstrated effectiveness in treating PAC/
PACG, but its overall efficacy and safety profile
seemed less favorable than that for PGA [16].
This study suggests that SLT may be effective in
patients with PAC and PACG with some portion
of the anterior chamber angle (ideally more
than 180) open to trabecular meshwork after
performance of laser iridotomy.
Pseudoexfoliation Glaucoma
In a recent prospective comparative study,
Miraftabi and colleagues investigated SLT effi-
cacy results in pseudoexfoliation glaucoma



















































































































































































































































































































































































































































































































































significantly higher percentage reduction in IOP
in the first 6 months following SLT in PXFG
eyes when compared with POAG (29% vs. 19%,
P = 0.02), while the efficacy of SLT in both types
of glaucoma had decreased at the 12-month
follow-up, with no significant difference in IOP
reduction between the two types (16% vs. 16%,
P = 0.9) at this time point. The success rates for
SLT in achieving an IOP reduction[20% at 6
and 12 months post-operation were comparable
between the types of glaucoma. There was no
significant reduction in the number of glau-
coma medications in either glaucoma type [17].
Lindegger et al. conducted a large-scale ret-
rospective chart review of 394 eyes with differ-
ent types of glaucoma that had undergone SLT.
The study included 94 eyes with PXFG. Patient
gender and age were taken into consideration in
the efficacy analysis, as PXFG is associated with
advanced age and female gender. Twelve
months following SLT, PXFG eyes showed
superior IOP reduction efficacy compared to
non-PXFG glaucomas, which included POAG,
normal-tension glaucoma (NTG), and pigmen-
tary glaucoma. The investigators noted signifi-
cant IOP reductions (12.3% and 9.6%) up to 21
and 30 months postoperatively in PXFG and
non-PXFG eyes, respectively [18].
Normal-Tension Glaucoma
Lee et al. have conducted two prospective
studies demonstrating favorable clinical out-
comes using SLT in Chinese patients with NTG
at 1- and 2-year follow-up. Patients enrolled in
the studies underwent medication washout
prior to determining their baseline IOP level. An
IOP reduction of [20% from the baseline
washout IOP without the addition of medica-
tion was considered absolute success [19, 20].
Forty-one right eyes were used in the analysis
of the 1-year study and 34 right eyes from the
same subject pool were included in the 2-year
study. Except for an occasional IOP spike at 1
week post-operation, IOP measured at all post-
operative time points was significantly reduced
compared with the pre-study level [19, 20]. At
12-month follow-up, the average IOP reduction
was 14.7% and medication reduction was 26.7%
from pre-study levels, and the absolute success
rate was 22% [19]. At 24-month follow-up, there
was an 11.5% reduction in IOP and 41.1%
reduction in glaucoma medication usage com-
pared with pre-study levels, and the absolute
success rate was 11.1% [20]. Although these
studies demonstrate a beneficial IOP-lowering
response in NTG, the efficacy remains lower
than what may be achieved in POAG, PXFG,
and pigmentary glaucoma.
Other Secondary Glaucomas
Several retrospective studies have demonstrated
the efficacy and safety of SLT in treating various
types of secondary glaucoma [21–24].
In a small retrospective study including 15
eyes with steroid-induced glaucoma in uveitic
eyes, SLT demonstrated a 46.7% success rate in
achieving IOP\22 mmHg and/or [20% IOP
reduction at all follow-up points up to
12 months. The mean reduction in IOP at
12 months was 50.4% [21].
Another retrospective study of 42 eyes
showed that SLT can be effective in treating
silicone-oil induced glaucoma. At 12-month
follow-up, 59.5% of eyes achieved [20% IOP
reduction without the addition of medications
or additional laser procedure or surgeries. The
mean IOP reduction was 20.3%, and the mean
number of glaucoma medications was signifi-
cantly reduced, from 2.17 ± 1.21 to 1.25 ± 0.89
(P\0.05) [22].
Two smaller studies by Sluch et al. and Zhang
et al. suggested a beneficial effect of SLT after
canaloplasty and trabeculectomy surgical pro-
cedures, respectively [20, 21]. Larger studies
with longer-term follow-up are needed to clarify
the role of SLT after incisional glaucoma
surgery.
PROGNOSTIC FACTORS
Several studies have investigated potential fac-
tors contributing to SLT success or failure in
various types of glaucoma.
Miki et al. conducted a retrospective study
that looked at success rate and factors con-
tributing to treatment success in Japanese
patients with open-angle glaucoma and
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receiving maximum-tolerable medical therapy.
The medical charts of 75 eyes of 59 patients
were reviewed up to 1 year postoperatively. The
results indicated that SLT achieved higher suc-
cess in patients with POAG than those with
secondary open-angle glaucomas (SOAG;
P\0.01). In addition, patients with lower pre-
operative IOP (P\0.01) and fewer preoperative
glaucoma medications (P\0.01) experienced
greater IOP reductions [25]. In contrast, in
another study that looked at the relationship
between preoperative IOP and SLT efficacy, a
mean preoperative IOP of[18 mmHg was
associated with a greater IOP reduction
(P = 0.002) than an IOP of 14–18 mmHg, and a
preoperative IOP of 14–18 mmHg led to better
IOP reduction (P = 0.03) than IOP\ 14 mmHg
[26]. Chun et al. also demonstrated higher
baseline IOP as a predictor of success [27]. After
adjusting the post-laser IOP of the treated eye
with the untreated eye in the same patient, the
IOP reduction was not as prominent, although
higher baseline IOP was predictive of significant
IOP reduction in both adjusted and non-ad-
justed eyes (IOP reduction of 23.1 ± 14.3%
and 26 ± 12.6%, respectively) [27]. Lee et al.
reported that in Hong Kong Chinese patients,
higher pre-SLT IOP was associated with treat-
ment success, although extremely high pressure
may not be effectively managed by SLT [12].
Most of the recent evidence points to a
higher success rate and/or greater IOP reduction
in eyes with higher baseline IOP up to a certain
level. The energy level employed in SLT therapy
may also be an important prognostic factor [28].
Age, gender, race, central corneal thickness,
history of ALT, history of cataract surgery, and
standard automated perimetry mean deviation
were not found to be associated with greater
IOP reduction after SLT [25–27]. Further study is
likely necessary to explore other potential
prognostic factors contributing to success after
SLT therapy.
SURGICAL TECHNIQUE
Standard SLT therapy employs an Nd: YAG laser
system with 400 lm spot size and three
nanoseconds of laser duration. An initial energy
level of 0.7–0.8 mJ is typically used, with upward
energy titration until bubble formation becomes
manifest. This energy level is considered the
threshold energy. Recommended energy settings
for conventional treatment are levels 0.1 mJ less
than the threshold energy [28, 29].
A recent prospective cohort study investi-
gated the optimal total SLT energy in 24 OAG
and 25 NTG eyes of Chinese patients. Total SLT
energy was defined as the number of SLT spots
multiplied by the mean energy level for the
treatment session. Here, 360-degree SLT was
performed in all subjects, with a mean of
171.5 ± 41.2 laser spots, mean energy level per
spot of 1.0 ± 0.06 mJ, and mean total energy of
167.1 ± 41.4 mJ. The average IOP reduction at
1 month following SLT was 20.2 ± 14.6%. A total
energy level of 226.1 mJ (95% confidence inter-
val: 214.58–234.87 mJ) was found to result in a
significant reduction in IOP greater than 25%
[28]. Results from this study suggest that a total
SLT energy level in the range of 214.6–234.9 mJ
may lead to higher success rates.
In another study investigating energy usage
in SLT, Zhang et al. treated two groups of
patients with 360-degree SLT with either con-
ventional energy levels or sub-threshold energy
(two-thirds of the conventional energy) levels.
The total energy was 51.8± 5.7 mJ in the con-
ventional treatment group and 37.6 ± 3.3 mJ in
the sub-threshold treatment (P = 0.036) group.
The IOP reduction and success rate following SLT
treatment at all follow-up visits was comparable
between the two groups up to 12 months post-
operatively. In addition, no significant difference
was detected between the two groups in the
degree of anterior chamber inflammation as
measured by the total protein content and cell
density for up to 1 month post-operation [29].
Geffen et al. studied transscleral SLT without
the use of a gonioscopy lens in patients with
POAG or PXFG in a prospective randomized
clinical trial. The study group received SLT
without a gonioscopy lens, and the control
group received conventional SLT therapy. After
6 months of follow-up, the mean postoperative
IOP and success rates of IOP reduction[15% or
[20% were similar between the two groups.
However, the study group demonstrated fewer
side effects, including anterior chamber
Ophthalmol Ther
inflammation and superficial punctate keratitis.
The authors suggest that transscleral SLT with-
out the use of a gonioscopy lens may be a more
efficient and safer technique, with therapeutic
potential comparable to that of the conven-
tional method [30].
There are limited data for comparing same--
day bilateral laser trabeculoplasty and sequen-
tial therapy [31]. An analysis of the use of laser
trabeculoplasty in Ontario during 2000–2013
showed that after the introduction of SLT, there
was a coincident increase in the number of
same-day bilateral laser trabeculoplasty proce-
dures in patients with POAG (4.9-fold increase).
However, sequential therapy is typically con-
sidered safer, as it gives treating physicians
opportunities to assess the efficacy and side
effects of the procedure on one eye before
treating the fellow eye [31].
In another prospective cohort study, 84 eyes
of 42 subjects with POAG or NTG underwent
bilateral SLT. The bilateral success rate was
42.9%, and there was a strong correlation
between the two eyes, while 38.1% of eyes had
bilateral non-success, with a moderate correla-
tion between the two eyes. Interestingly, if
success was achieved in one eye but not in the
fellow eye, there was strong negative correlation
between the two eyes. In the majority of eyes,
the success or non-success of one eye may pre-
dict the clinical outcome of the fellow eye [32].
Greninger et al. investigated efficacy and
safety outcomes after SLT performed by resident
physicians. The investigators recruited 15 resi-
dent physicians to perform SLT in 81 patients.
There was significant IOP reduction (P\0.001),
ranging from 12% to 19%, and success rates
ranging from 36% to 50% after 3–24 months of
follow-up. An IOP spike following the proce-
dure was seen in 7% of the eyes. Both efficacy
and complication rates were comparable to
attending-performed SLT in the literature,
regardless of whether the resident had had
experience with SLT prior to this study [33].
POSTOPERATIVE CARE
No consensus statement exists regarding the
postoperative management of patients after SLT
therapy. Some ophthalmologists choose to use a
short course of anti-inflammatory medications,
but such practice has not been validated
[34, 35].
Two randomized clinical trials have investi-
gated the use of anti-inflammatory eye drops,
including non-steroid anti-inflammatory drugs
(NSAIDs) and steroid medications, after SLT.
Neither of these studies found a significant dif-
ference in postoperative outcome among
patients randomized to postoperative anti-in-
flammatory medications vs. either placebo (ar-
tificial tears) or no treatment [34, 35]. In the
study by De Keyser et al., patients with POAG,
NTG, or OHT served as their own self-control,
and both eyes received 360-degree SLT treat-
ment within a 1-week period. The study group
reported that the use of indomethacin or dex-
amethasone was not associated with a signifi-
cant difference in patients’ postoperative
comfort level, conjunctival hyperemia, rate of
IOP spike at 1 h, or efficacy of treatment [34]. In
the second trial, Jinapriya et al. investigated the
effect of prednisone 1% and ketorolac 0.5%
compared with placebo eye drops on IOP
reduction in patients with open-angle or
pseudo-exfoliation glaucoma after 180-degree
treatment of SLT. Reduction in IOP at 1 month
post-operation, treatment failure rates, and
anterior chamber inflammation were not found
to be significantly different across the groups.
The investigators emphasized that the mean
baseline IOP of the patients was 19.1 mmHg,
which they considered a relatively low baseline,
but that it should not have altered the com-
parison of treatment efficacy among the groups
[35].
Given the findings to date, it is still too early
to conclude whether anti-inflammatory medi-
cations should be used in the postoperative care
of patients undergoing SLT. Larger studies that
include a variety of glaucoma subtypes and
different surgical techniques may be necessary
to further investigate this issue.
REPEATABILITY
As IOP reduction wanes after initially successful
SLT therapy, questions remain regarding the
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utility of repeat treatment. Three recent retro-
spective studies sought to answer this question
by investigating the safety and efficacy of repeat
SLT treatments. All three studies showed that
mean IOP following both initial and repeat SLT
was significantly reduced from baseline IOP,
although there were discrepancies in the mag-
nitude of IOP reduction and the success rate of
repeat SLT compared to the initial SLT treat-
ment. Neither initial nor repeat SLT resulted in
a significant reduction in the number of glau-
coma medications among the studies [3–5].
Francis et al. studied 137 eyes of 137
patients, which was a much larger number of
subjects than in the other studies. The investi-
gators defined success of repeat SLT therapy as
either (1) an IOP between 5 and 21 mmHg, with
at least 20% IOP reduction and with no addi-
tion of glaucoma medications, or (2) an IOP
between 5 and 21 mmHg, with IOP reduction of
at least 20% or reduction in glaucoma medica-
tion use, without other procedures. With dif-
ferent IOP baselines (P = 0.03) between initial
(SLT1) and repeat (SLT2) SLT, initial treatment
seemed to have a higher success rate than repeat
treatment by both definitions. However, when
the baseline IOP of initial and repeat SLT were
matched, the IOP reduction and success rate did
not differ significantly between treatments
(definition 1: SLT1—43% at 6 months and 20%
at 12 months, SLT2—44% at 6 months and 20%
at 12 months; definition 2: SLT1—57% at
6 months and 33% at 12 months, SLT2—52% at
6 months and 28% at 12 months). The per-
centage IOP reductions at 12-month follow-up
for SLT1 and SLT2 were similar regardless of
whether the baseline IOP values were matched.
The success rate by both definitions was signif-
icantly higher when there was a shorter interval
between initial and repeat SLT at all follow-up
visits (P\0.01). In one of their sub-analyses, the
investigators reported that the reduction in IOP
after either initial or repeat SLT was not affected
by whether the patients had undergone ALT,
which provides more insight into treating
patients who have had ALT with SLT in the past
[3].
In a study by Khouri et al., repeat SLT was
effective in lowering IOP up to 24 months after
treatment, and the IOP reduction was similar to
that of the initial treatment. However, at 4, 8,
and 12 months post-operation, there was
greater reduction (P\0.05) with the initial
treatment than with the repeat treatment. In
addition, a lower success rate was achieved
(P\0.05) for eyes experiencing an IOP reduc-
tion[20% and 15% from baseline with repeat
treatment at all time points except 18 and
24 months post-operation, where the effect of
both initial and repeat treatments wore off. At
24 months, there was a 29–30% success rate
after repeat SLT therapy [4].
Polat et al. also studied repeatability of
selective laser trabeculoplasty and defined suc-
cess as either (1) IOP control without additional
glaucoma medication or other procedures, or
(2) IOP reduction by at least 20%. In 38 eyes
with OAG uncontrolled on maximum medical
therapy, the median survival rate with repeat
SLT treatment (definition 1: 1054 days; defini-
tion 2: 360 days) was found to be longer than
with the initial SLT treatment (definition 1:
570 days; definition 2: 270 days) by both defi-
nitions. Efficacy of both initial and repeat SLT
was present throughout the 24-month fol-
low-up. The IOP reduction was not significantly
different between initial and repeat SLT at any
time point. This study also demonstrated the
relative safety of repeat SLT, as it was not asso-
ciated with an IOP spike of more than 10 mmHg
or anterior chamber inflammation [5].
COMPLICATIONS
A recent review study summarized some of the
reported complications of SLT. These include
transient IOP spike, iritis, hyphema, macular
edema, foveal burn, and corneal haze [9]. In
addition, some uncommon complications of
SLT have been discussed in case reports
[10, 11, 36]. Recent data pertaining to compli-
cations related to SLT are summarized in
Table 2.
Several original studies have elucidated pos-
sible transient changes in the cornea following
SLT [11, 37–39]. These include changes in cor-
neal thickness, corneal hysteresis, and
endothelial cell function [10, 11, 37–39]. Ante-
rior chamber volume (ACV) and macular
Ophthalmol Ther
Table 2 Complications of SLT





Case report OAG Two patients Corneal edema secondary to herpetic stromal
keratitis without known history of herpes
ophthalmicus or oral ulcers prior to the SLT
treatment
Bettis et al. [11] Case series Exfoliation
glaucoma
Five patients Postoperative corneal edema, corneal
endothelial injuries. IOP elevation persisting
weeks to months and up to 39–48 mmHg







n = 59 (PAC/
PACG), n = 59
(POAG)
IOP increase of 10 mmHg in 10% of PAC/






PAC/PACG n = 96 (SLT),
n = 99 (PGA)
IOP increase[5mmgHg in 2% of PAC/
PACG patients 30–60 min following SLT





n = 42 IOP increase[6 mmHg of 26.2% of eyes on
the same day as SLT treatment








n = 132 SLT induced little inﬂammation (e.g. pain,
redness, cells in anterior chamber, transient
IOP spike)
Transient IOP increase[5 mmHg in 3–8.5%
of patients
Baser et al. [36] Case report POAG Two patients PAS following repeat SLT
Atalay et al. [37] Retrospective
chart review
POAG n = 33 3–6 months following SLT, signiﬁcant changes
in CCT, thinnest point of cornea, and
posterior corneal asphericity at 5 and 8 mm







n = 45 1 month following SLT, signiﬁcant increase in
CCT and decrease in ACV (P\0.05); both





OAG n = 52 Signiﬁcant increase in CH (P = 0.028) and
decrease in CRF (P = 0.037); neither is
signiﬁcant after adjusting for IOP reduction
Koc et al. [40] Prospective
randomized
clinical trial
POAG n = 40 Temporary increase in macular thickness in
three quadrants, which returned to baseline
at 1-month follow-up
ACV chamber corneal volume, CCT central corneal thickness, CH corneal hysteresis, CRF corneal resistance factor, IOP
intraocular pressure, NTG normal-tension glaucoma, OAG open-angle glaucoma, OHT ocular hypertension, PAC primary
angle closure, PACG primary angle-closure glaucoma, PAS peripheral anterior synechiae, PGA prostaglandin, POAG
primary open-angle glaucoma, SLT selective laser trabeculoplasty
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thickness have also been shown to change
transiently after SLT [38, 40]. Baser et al. repor-
ted on two cases of peripheral anterior syne-
chiae (PAS) as a complication of SLT. In the two
patients with POAG, there were no PAS noted
after successful initial SLT. The PAS were
detected 3-6 months following the repeat SLT
treatment [36].
The incidence of a transient IOP spike after
SLT has been investigated in several studies. In
the majority of these, an increase in IOP was
detected only on the day of the SLT procedure
and was controlled by medications and not
considered a long-term complication. Roughly
2–26.2% of glaucoma patients experienced a
temporary postoperative IOP spike
[15, 16, 22, 34]. In Ali Aljasim et al.’s study, an
IOP spike of 10 mmHg was detected in 10% of
PAC/PACG patients and 5% of POAG patients 1
h after the procedure [15]. Narayaaswamy et al.
reported an increase in IOP greater than 5 mmHg
in 2% of PAC/PACG patients 30–60 min follow-
ing SLT [16]. A transient IOP spike greater than
5 mmHg 1 h following SLT was detected in
3–8.5% of patients in a study by De Keyser et al.
[34]. In patients with silicone oil-induced glau-
coma, 26.2% of eyes experienced an IOP spike
greater than 6 mmHg on the same day as the
treatment [22]. Longer-term IOP elevation was
reported in a case series of five patients with
exfoliation glaucoma, with IOP elevation per-
sisting weeks to months and up 39-48 mmHg.
All patients required surgical intervention with
trabeculectomy with mitomycin C and/or aque-
ous shunt implantation [11].
CONCLUSION
Recent findings pertaining to SLT therapy have
demonstrated its benefits and advantages in
treating glaucoma, yet there are still unan-
swered questions. Its effectiveness in various
types of glaucoma has tremendous clinical
value. Studies that have examined the postop-
erative care and repeatability of SLT provide
insight in terms of the long-term application of
this procedure in glaucomatous individuals.
Physicians should be familiar with common
and rare but significant complications of SLT in
order to provide comprehensive information to
the patients and to be prepared to address pos-
sible issues following the procedure. As SLT
remains a powerful tool in treating glaucoma,
more evidence will emerge to further improve
clinical outcomes and patient care.
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